These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15665289)

  • 1. Thymosin {beta}(10) inhibits angiogenesis and tumor growth by interfering with Ras function.
    Lee SH; Son MJ; Oh SH; Rho SB; Park K; Kim YJ; Park MS; Lee JH
    Cancer Res; 2005 Jan; 65(1):137-48. PubMed ID: 15665289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG; Kim TD; Li G; Yoon WH; Chae CB
    Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide.
    Ferrari N; Pfeffer U; Dell'Eva R; Ambrosini C; Noonan DM; Albini A
    Clin Cancer Res; 2005 Jun; 11(12):4610-9. PubMed ID: 15958647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.
    Polverino A; Coxon A; Starnes C; Diaz Z; DeMelfi T; Wang L; Bready J; Estrada J; Cattley R; Kaufman S; Chen D; Gan Y; Kumar G; Meyer J; Neervannan S; Alva G; Talvenheimo J; Montestruque S; Tasker A; Patel V; Radinsky R; Kendall R
    Cancer Res; 2006 Sep; 66(17):8715-21. PubMed ID: 16951187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activin A suppresses neuroblastoma xenograft tumor growth via antimitotic and antiangiogenic mechanisms.
    Panopoulou E; Murphy C; Rasmussen H; Bagli E; Rofstad EK; Fotsis T
    Cancer Res; 2005 Mar; 65(5):1877-86. PubMed ID: 15753386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenesis and anticancer efficacy of TA138, a novel alphavbeta3 antagonist.
    Mousa SA; Mohamed S; Wexler EJ; Kerr JS
    Anticancer Res; 2005; 25(1A):197-206. PubMed ID: 15816539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic activity of beta-eudesmol in vitro and in vivo.
    Tsuneki H; Ma EL; Kobayashi S; Sekizaki N; Maekawa K; Sasaoka T; Wang MW; Kimura I
    Eur J Pharmacol; 2005 Apr; 512(2-3):105-15. PubMed ID: 15840394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the tyrosine phosphatase SHP-2 suppresses angiogenesis in vitro and in vivo.
    Mannell H; Hellwig N; Gloe T; Plank C; Sohn HY; Groesser L; Walzog B; Pohl U; Krotz F
    J Vasc Res; 2008; 45(2):153-63. PubMed ID: 17962719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoestoxide, a natural nonmutagenic diterpenoid with antiangiogenic and antitumor activity: possible mechanisms of action.
    Ojo-Amaize EA; Nchekwube EJ; Cottam HB; Bai R; Verdier-Pinard P; Kakkanaiah VN; Varner JA; Leoni L; Okogun JI; Adesomoju AA; Oyemade OA; Hamel E
    Cancer Res; 2002 Jul; 62(14):4007-14. PubMed ID: 12124334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway.
    Jung MH; Lee SH; Ahn EM; Lee YM
    Carcinogenesis; 2009 Apr; 30(4):655-61. PubMed ID: 19228635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
    Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
    Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HB-EGF stimulates eNOS expression and nitric oxide production and promotes eNOS dependent angiogenesis.
    Mehta VB; Zhou Y; Radulescu A; Besner GE
    Growth Factors; 2008 Dec; 26(6):301-15. PubMed ID: 18925469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic and antitumoral activity of phenyl-3-(2-chloroethyl)ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance.
    Petitclerc E; Deschesnes RG; Côté MF; Marquis C; Janvier R; Lacroix J; Miot-Noirault E; Legault J; Mounetou E; Madelmont JC; C -Gaudreault R
    Cancer Res; 2004 Jul; 64(13):4654-63. PubMed ID: 15231678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis.
    Lovren F; Pan Y; Shukla PC; Quan A; Teoh H; Szmitko PE; Peterson MD; Gupta M; Al-Omran M; Verma S
    Am J Physiol Endocrinol Metab; 2009 Jun; 296(6):E1440-9. PubMed ID: 19351806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
    Chung TW; Kim SJ; Choi HJ; Kim KJ; Kim MJ; Kim SH; Lee HJ; Ko JH; Lee YC; Suzuki A; Kim CH
    Glycobiology; 2009 Mar; 19(3):229-39. PubMed ID: 18974200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of angiogenesis and vascular leakiness by angiopoietin-related protein 4.
    Ito Y; Oike Y; Yasunaga K; Hamada K; Miyata K; Matsumoto S; Sugano S; Tanihara H; Masuho Y; Suda T
    Cancer Res; 2003 Oct; 63(20):6651-7. PubMed ID: 14583458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EPOX inhibits angiogenesis by degradation of Mcl-1 through ERK inactivation.
    Sun HL; Tsai AC; Pan SL; Ding Q; Yamaguchi H; Lin CN; Hung MC; Teng CM
    Clin Cancer Res; 2009 Aug; 15(15):4904-14. PubMed ID: 19622586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.